Novavax Inc. (NASDAQ:NVAX) Relative Strength Index (RSI) is 47.69, with weekly volatility at 8.83% and ATR at 14.57. The NVAX stock’s 52-week price range has touched low of $55.02 and a $331.68 high. Intraday shares traded counted 2.84 million, which was 23.91% higher than its 30-day average trading volume of 3.73M. Its shares traded lower over the last trading session, losing -3.05% on 06/18/21. The shares fell to a low of $170.51 before closing at $174.41. NVAX’s previous close was $179.89 while the outstanding shares total 73.03M. The firm has a beta of 1.56.
Investors have identified the Biotechnology company Novavax Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $13.33 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Novavax Inc. (NVAX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 2.25 billion total, with 1.21 billion as their total liabilities.
NVAX were able to record 649.3 million as free cash flow during the 08/10/2021 quarter of the year, this saw their quarterly net cash flow reduce by 1.38 billion. In cash movements, the company had a total of 663.09 million as operating cash flow.
Potential earnings growth for Novavax Inc. (NVAX)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/10/2021 quarter of the year, Novavax Inc. recorded a total of 447.23 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 99.24% coming in sequential stages and their sales for the 08/10/2021 quarter increasing by 37.47%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 447.23 million trying to sell their products during the last quarter, with the result yielding a gross income of 655.86 million. This allows shareholders to hold on to 73.03M with the recently reported earning now reading -3.05 cents per share. This is a figure that compared to analyst’s prediction for their 08/10/2021 (-3.05 cents a share).
Having a look at the company’s valuation, the company is expected to record 30.21 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on NVAX sounds very interesting.
Is the stock of NVAX attractive?
In related news, President, R&D, Glenn Gregory M sold 2,411 shares of the company’s stock in a transaction that recorded on Jun 17. The sale was performed at an average price of 183.28, for a total value of 441,887. As the sale deal closes, the President, R&D, Glenn Gregory M now sold 5,716 shares of the company’s stock, valued at 1,094,130. Also, Director, EVANS GARY C sold 625 shares of the company’s stock in a deal that was recorded on Jun 01. The shares were price at an average price of 146.50 per share, with a total market value of 91,562. Following this completion of acquisition, the EVP, Chief Legal Officer, Herrmann John A III now holds 2,895 shares of the company’s stock, valued at 431,748. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.20%.
4 out of 6 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on Novavax Inc.. 0 analysts has assigned a Sell rating on the NVAX stock. The 12-month mean consensus price target for the company’s shares has been set at $258.00.